CRC Screening Program
Colorectal Cancer Screening
CommercialActive
Key Facts
About Polymedco
Polymedco is a commercial-stage, privately-held diagnostics company with a 40-year history focused on screening and early detection. Its core business revolves around two flagship product lines: the OC-Auto® FIT system for colorectal cancer (CRC) screening and the PATHFAST® Cardiac Biomarker Analyzer for point-of-care cardiac testing. The company leverages robust clinical evidence and programmatic support to drive patient compliance and improve clinical outcomes, positioning itself as a partner to healthcare systems and laboratories. Its strategy is built on delivering user-friendly, high-performance tests backed by extensive data and customer-centric implementation services.
View full company profileTherapeutic Areas
Other Colorectal Cancer Screening Drugs
| Drug | Company | Phase |
|---|---|---|
| Shield (ECLIPSE Study) | Guardant Health | FDA Approved |
| Urine cfDNA Test for Colon Cancer Screening | JBS Science | Development |
| iFOB | Pangea Laboratory | Commercial |
| ColoHealth | New Day Diagnostics | Approved |
| SimpleScreen CRC | Freenome | Commercial (as LDT) |
| ColoScape™ / QuantiDNA™ | DiaCarta | Commercial |
| ColoSense | Geneoscopy | Approved |
| At-Home Colorectal Cancer Screening | SNT Biotech | Commercial |
| FIT System & Assay Development | Sentinel Diagnostics | Commercial |
| Next-Generation Cologuard® | Exact Sciences | Development |
| ColoAlert® | Mainz Biomed | Pivotal Trial |